Drug Discovery Opportunities
Our proprietary drug discovery platform has generated a wide range of novel chemistries that we believe will continue to provide us with starting points for additional drug programs. We have identified novel chemistries for more than 100 distinct targets. Using these target-specific chemistries, we have established a portfolio of proprietary drug discovery assets and projects in four key therapeutic areas. In each of these areas, we have identified novel chemistries for several different drug targets that we believe play an important role in these major diseases. The following table illustrates examples of targets where we have discovered novel chemistries.
Therapeutic Area
--------------------------------------------------------------------------------
Targets with Novel Chemistry
--------------------------------------------------------------------------------
Neuropsychiatry
mGluR5, muscarinic, serotonin, neuropeptides
Neuropathic pain, inflammation
NPFF2, Mrg, PAR2, lipoxin
Endocrinology
AR, ERß, ERR, Ghrelin, RAR
Metabolic syndrome
LXR, SSR5, HNF4alpha
Our discovery projects aim to answer specific scientific questions using relatively-limited synthetic chemistry and biological efforts. When all key criteria have been fulfilled, these earlier-stage discovery projects may be advanced into preclinical programs.
(snip) |
